Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch from etravirine to doravirine in virologically suppressed HIV-1 adults with etravirine resistance
2022-001591-33Phase 4Terminated
- Sponsor
- Fundació Clínic per a la Recerca Biomèdica
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of doravirine in human immunodeficiency virus infection (HIV), sponsored by Fundació Clínic per a la Recerca Biomèdica. Primary endpoint: Percentage of participants with confirmed viral load >50 copies/mL at week 48. Started Jul 2022; status: terminated.
02
Drugs
doravirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2022-001591-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001591-33.